The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SI-BONE Inc is $23.50, about 32.3% above its July 31 closing price of $17.76
Quarterly results
US medical device maker's Q2 revenue rose 15% yr/yr, beating analyst expectations
Adjusted EBITDA for Q2 improved 178% to positive $2.8 mln
Q2 revenue was $56.01 mln, versus consensus estimate of $55.34 mln (9 analysts)
Q2 net loss was $4.09 mln
Q2 gross margin was 79.50%
Q2 loss per basic share was $0.09
Q2 operating expenses were $49.35 mln
Q2 operating income was -$4.81 mln
Outlook and drivers
SI-BONE raises 2026 revenue guidance to $231 mln-$233 mln, up from $230 mln-$233 mln
Company now sees 2026 revenue growth of 15%-16% yr/yr
Company maintains 2026 gross margin guidance at about 79%
SIBN•
